secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0000950170-24-060449
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Holdings shareholders approve amended 2023 Incentive Equity Plan
-----------------------------------------------------------------------

- Shareholders approved amended 2023 Incentive Equity Plan with 25,623,625 votes for and 2,586,367 against at May 15 annual meeting.
- Plan amendment changes evergreen provision to annual increase of 5% of outstanding common shares (or smaller as determined by committee).
- Directors Paul Hastings (28,201,063 for), Wouter Joustra (28,212,507 for), and Lota Zoth (28,212,007 for) elected.
- Appointment of auditor approved with 28,467,217 votes for, no against or abstentions.
- Amended plan filed as Exhibit 10.1; effective upon shareholder approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/0000950170-24-060449-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024060449/engn-20240515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-060449

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer